| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | ML; TPO; MGDF; MKCSF; MPLLG |
| Entrez GeneID | 7066 |
| clone | 1B11 |
| WB Predicted band size | 37.8kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human THPO expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于THPO抗体的3篇参考文献及其摘要：
1. **文献名称**：*Thrombopoietin: The Primary Regulator of Platelet Production*
**作者**：Kaushansky, K.
**摘要**：该综述详细阐述了血小板生成素(THPO)在调控巨核细胞分化和血小板生成中的核心作用，并讨论了抗THPO抗体在诊断血小板减少症(如免疫性血小板减少症，ITP)中的潜在应用，强调其作为生物标志物的可能性。
2. **文献名称**：*Romiplostim in Thrombocytopenic Patients: Clinical Efficacy and Antibody Development*
**作者**：Bussel, J.B. 等
**摘要**：研究报道了TPO受体激动剂romiplostim(重组THPO模拟抗体)在慢性ITP患者中的临床试验结果，显示其显著提升血小板计数，且未检测到中和性抗THPO抗体的产生，支持其长期治疗安全性。
3. **文献名称**：*Autoantibodies Against Thrombopoietin in Immune Thrombocytopenia*
**作者**：McMillan, R. 等
**摘要**：该研究发现部分ITP患者血清中存在抗THPO自身抗体，这些抗体通过抑制THPO与受体结合导致血小板生成减少，揭示了ITP病理机制的新视角，并为靶向治疗提供依据。
Thrombopoietin (THPO) is a glycoprotein hormone primarily produced in the liver and kidneys, playing a critical role in regulating platelet production by binding to the c-MPL receptor on megakaryocytes, promoting their proliferation and differentiation. THPO antibodies, which target this hormone or its receptor, have garnered attention in both research and clinical contexts. In diagnostic settings, anti-THPO antibodies are used to measure THPO levels in conditions like thrombocytopenia or myeloproliferative disorders, where dysregulated THPO signaling may contribute to abnormal platelet counts.
Autoantibodies against THPO or c-MPL are implicated in certain autoimmune disorders, such as immune thrombocytopenia (ITP), where they disrupt normal thrombopoiesis. Additionally, therapeutic anti-THPO receptor agonists (e.g., romiplostim, eltrombopag) mimic THPO activity to stimulate platelet production, offering treatment for chronic ITP or chemotherapy-induced thrombocytopenia. Conversely, neutralizing antibodies against THPO or its receptor are explored in conditions with pathological platelet overproduction, such as essential thrombocythemia. Research on THPO antibodies continues to unravel their pathophysiological roles and therapeutic potential, bridging hematopoiesis regulation with clinical applications in hematologic diseases.
×
